- Report
- April 2025
- 175 Pages
Global
From €3970EUR$4,490USD£3,425GBP
- Report
- April 2025
- 175 Pages
Global
From €3970EUR$4,490USD£3,425GBP
- Report
- March 2025
- 200 Pages
Global
From €3970EUR$4,490USD£3,425GBP
- Report
- April 2025
- 175 Pages
Global
From €3970EUR$4,490USD£3,425GBP
- Report
- March 2025
- 150 Pages
Global
From €2874EUR$3,250USD£2,479GBP
€4288EUR$4,850USD£3,699GBP
- Report
- July 2025
- 277 Pages
Global
From €5172EUR$5,850USD£4,462GBP
- Report
- May 2025
- 230 Pages
United States
From €2476EUR$2,800USD£2,136GBP
€3537EUR$4,000USD£3,051GBP
- Report
- September 2023
- 112 Pages
Europe
From €3050EUR$3,450USD£2,631GBP
- Report
- November 2023
- 114 Pages
Global
From €3500EUR$4,240USD£3,125GBP
Rotarix is a vaccine used to protect against rotavirus, a virus that causes severe diarrhea in infants and young children. It is a live, oral vaccine that is administered in two doses, typically given at two and four months of age. The vaccine is approved for use in over 100 countries and is recommended by the World Health Organization (WHO) as part of the routine immunization schedule for infants.
Rotarix is a part of the larger global vaccine market, which includes a variety of products used to protect against a range of infectious diseases. Vaccines are an important tool in public health, helping to reduce the spread of disease and protect vulnerable populations.
The Rotarix market is dominated by a few large pharmaceutical companies, including GlaxoSmithKline, Merck, and Sanofi Pasteur. Other companies, such as CSL and Pfizer, also produce rotavirus vaccines. Show Less Read more